Tag Archives: hcv

Gilead HCV Combo Hits In Trials, Could Broaden Market

Gilead Sciences (GILD) said Monday that its two-drug combo had succeeded against six different genotypes of the hepatitis C virus (HCV) in four late-stage clinical trials. Gilead’s studies combined sofosbuvir — which is sold separately as Sovaldi and is also an ingredient in Harvoni — with a new drug candidate called velpatasvir. Some cohorts took ribavirin, an older HCV pill, in place of velpatasvir. The patients on sofosbuvir/velpatasvir for 12

Gilead Gets Wall Street Love After Q2 Earnings Beat

Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and the increased guidance, from a company known for conservative forecasting. Piper Jaffray analyst Joshua Schimmer raised his price target on Gilead stock to 134 from 131 based on the news. “While the

Achillion, J&J To Jointly Develop Hepatitis C Drugs

Small biotech Achillion Pharmaceuticals (ACHN) announced late Tuesday that it had entered a collaboration with Johnson & Johnson (JNJ) to develop its hepatitis C drugs, potentially worth more than $1 billion. J&J agreed to invest $225 million in Achillion upfront, and promised up to $1.1 billion in development, regulatory and sales milestone payments if the companies successfully launch their pipeline of drugs treating the hepatitis C virus (HCV).